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Abstract
Fibrosis, a phenotype associated with mortality for a multitude of diseases, has no
disease-modifying treatment. We examine if Verteporfin (VP), an inhibitor of the YAPTEAD complex, currently in wide clinical use for macular degeneration, can inhibit profibrotic gene expression in human dermal fibroblasts. Also, an in vivo approach was
taken using a Pten-deficient mouse of progressive skin fibrosis for examining effects on
melanoma metastasis. We found that treatment with VP reduced basal expression of a
variety of profibrotic genes and prevented a myofibroblast-like phenotype in response to
TGFβ1. Indeed, genome-wide expression analysis suggested that VP inhibited a cluster
of profibrotic genes with and without added TGFβ1. Preliminary analysis of metastasis to
the lung of melanoma tumors in Pten-deficient mice showed a trend towards increased
metastasis the absence of Pten expression by fibroblasts; i.e., in a fibrotic
microenvironment. My findings support targeting YAP as a potential treatment for
fibrotic diseases.
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Summary for Lay Audience
Pathological fibrosis is the progressive stiffening of skin or other organs,
ultimately interfering with organ function and resulting in death. Pathological fibrosis is
involved with 45% of mortalities in the developed world and has no available treatment.
Progressive stiffening of the tissue is characterized by the progressive differentiation of
local cells known as fibroblasts into stiff cells known as myofibroblasts. These cells exert
mechanical tension onto themselves and the scaffolding around cells known as the
extracellular matrix. This effect is involved in normal processes such as wound repair,
however in fibrotic disease, it becomes dysregulated. The progressive increase of tension
in the tissue also changes gene expression of proteins in the cell. The most well-known
protein that is produced in cases of fibrotic disease is CCN2. This protein is known to
bind to the cell surface and is thought to prevent the resolution of cellular stiffness. In
fact, CCN2 also functions to transition more cells into myofibroblasts and increase tissue
stiffness, creating a positive-feedback loop. Increased stiffness seen in fibrotic disease
highly reflects the tumor microenvironment, the scaffolding around cancerous cells, and
is thought to aid the migration of tumor cells to other locations in the body. Recent
research has pointed towards YAP as a central mediator of fibrotic gene expression,
including CCN2. Here, we repurposed Verteporfin, a drug currently on the market for
macular degeneration, as an inhibitor of YAP. Administering Verteporfin to fibroblasts
prevented differentiation into myofibroblasts normally induced by TGFβ1. A mass
analysis of gene expression revealed that inhibiting YAP with Verteporfin reduced
expression of many known fibrosis-related genes, including CCN2. These findings
support YAP as a central mediator of fibrosis, and repurposing Verteporfin to inhibit
YAP could be a viable therapeutic strategy with relatively little financial investment. To
test the ability of a fibrotic microenvironment to enhance cancer metastasis, we used a
mouse model with silenced Pten, a cellular signaling protein upstream from Yap in the
cellular signaling pathway, to induce spontaneous fibrosis. However, the induced fibrotic
phenotype was not as stiff as expected, and the results were inconclusive.
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Introduction
1.1

Fibrosis

Fibrosis, the final pathological outcome of many chronic inflammatory diseases,
involved with nearly 45% of all deaths in the developed world. There is no available
anti-fibrotic treatment that blocks and/or reverses disease progression (Wynn, 2007;
Wynn et al., 2012). In normal tissue repair, inflammation occurs in response to injury in
three distinct phases. The first is an early proinflammatory step, in which the release of
cytokines recruits neutrophils, monocytes, and other innate immune cells to the site of
injury. In the second phase, the proinflammatory response begins to subside and key
inflammatory cells such as macrophages switch to a reparative phenotype. In the final
step, the inflammatory response is resolved with inflammatory cells exiting the site of
lesion or are eliminated through apoptosis. (Eming et al., 2017). Wound repair
macrophages are characterized by the enhanced production of numerous growth factors,
including platelet derived (PDGF), insulin-like (IGF-1), and vascular endothelial (VEGFα), which promote cell proliferation and blood vessel development (Shimokado et al.,
1985; Rappolee et al., 1988; Berse et al., 1992; Chujo et al., 2009; Willenborg et al.,
2012). They also produced transforming growth factor beta one (TGFβ1), which
stimulates local and recruited fibroblasts into myofibroblasts that facilitate wound
contraction and closure, as well as the synthesis of extracellular matrix (ECM)
components (Akhurst et al., 2012). In normal tissue repair, myofibroblasts are resolved
through apoptosis (Leight et al., 2012), and recruited cells are returned to their original
state. Production of the ECM is balanced with degradation of the ECM through the action
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of matrix metalloproteinases (MMPs) (Gill et al., 2008). Pathological fibrosis is
characterized by the excess deposition of extracellular matrix (ECM) components by
myofibroblasts, such as collagen and fibronectin, in an organ or tissue. Normal tissue
repair can turn into an irreversible fibrotic response in cases of severe or repetitive injury,
or in cases where the wound healing response becomes dysregulated (Wynn et al., 2012).
Progressive fibrosis results in gradual loss of organ function due to the replacement of
functional tissue with scar tissue, and is the major cause of morbidity in individuals with
systemic sclerosis (SSc) (Ho et al., 2014).

1.2

Systemic sclerosis (SSc)

Systemic sclerosis (SSc), also referred to as scleroderma, is an auto-immune
rheumatic disease that is characterized by progressive fibrosis of the skin, internal
organs and vasculature. Although uncommon, it has high morbidity and mortality. As
the etiology of SSc fibrosis is unknown, treatment options are limited to those that
target disease symptoms (Denton et al., 2017). Genome-wide expression profiling of
SSc skin revealed that the disease is highly heterogeneous, with patients subdivided
into either “fibroproliferative” or “inflammation/innate immunity” cohorts based on
the overexpression of genes compared to individuals without SSc (Milano et al., 2008).
Altered expression of genes associated with transforming growth factor beta (TGFβ)
and Wnt signaling are commonly seen in fibroblasts cultured from SSc skin biopsy
samples; these genes appear to be overexpressed in the fibroproliferative cohort of SSc
patients (Gardner et al., 2006). Sustained, localized inflammation, vascular damage and
the resultant presence of local and systemic profibrotic growth factors/cytokines facilitate
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the differentiation of resident fibroblasts (and possibly recruited cells, including
pericytes, fibrocytes and endothelial/adipogenic progenitor cells) into α-smooth muscle
actin (SMA)-expressing myofibroblasts. The latter are considered the effector cells of
fibrosis, which deposit and remodel large quantities of ECM components (Trojanowska,
2010) (Figure 1.1). Thus, induction of myofibroblasts is also promoted by the increased
ECM stiffness inherent to the scar tissue, although it is unclear the extent to which ECM
stiffness acts upstream or in parallel to the effect of growth factors and cytokines on
fibroblasts.

1.3

The myofibroblast

Myofibroblasts, the primary type of cells that produce ECM in response to injury in
every organ of the body, produce high levels of α-smooth muscle actin (SMA)-containing
stress fibers, which are highly contractile. These fibers are linked to the surrounding
ECM through focal adhesions, and transduce mechanical tension from the ECM to the
myofibroblast (Bissell, 1998; Koivisto et al., 2014; Hinz, 2016). In normal wound repair,
TGFβ-induced myofibroblasts are resolved through apoptosis or deactivation after wound
repair is completed. However, should this program persist or be aberrantly activated,
fibrotic responses result. For example, when endothelial cells are injured, an extra-
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Figure 1.1 Model of myofibroblast differentiation in fibrotic lesions
Profibrotic growth factors such as TGFβ1 stimulate differentiation of resident fibroblasts
into α-SMA expressing myofibroblasts, which display elevated integrin/focal adhesion
kinase (FAK) mediated extracellular matrix (ECM) contraction. Myofibroblasts
excessively deposit collagen and other pro-fibrotic components, such as cellular
communication network factor 2 (CCN2), which stiffen the ECM. Some pro-fibrotic
components signal back on other resident fibroblasts to stimulate further myofibroblast
differentiation and ECM stiffness, thus creating a pro-fibrotic autocrine signaling loop. If
the production of these mechano-sensitive factors is regulated by YAP, then intervention
with verteporfin (VP) may break the autocrine pro-fibrotic loop and provide a therapeutic
benefit.
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domain A (EDA)-containing isoform of fibronectin is released, which recruits and
activates progenitor cells that differentiate into myofibroblasts, failing to senesce after the
initial stimulus is removed (Hutchenreuther et al., 2016). These myofibroblasts then
excessively deposit and remodel collagen and other ECM components, resulting in
increased ECM stiffness, which further acts on myofibroblasts. Thus, myofibroblasts are
maintained by an autocrine, pro-adhesive signaling loop. Supporting this notion,
myofibroblasts cultured from lesion areas of SSc patients, compared to fibroblasts from
unaffected areas of SSc patients or with healthy individuals, excessively adhere to and
contract the ECM (Thannickal et al., 2003; Leask, 2012). Overall, the available data
suggest that mechanical tension from the ECM acting on the fibroblast may initiate and
perpetuate the fibrotic phenotype through a process known as mechanotransduction.

1.4

Integrin β1-mediated mechanotransduction

Fibroblasts involved in fibrotic lesions develop stronger attachments to the ECM
through structures called focal adhesions (FAs). These attachments signal through
clusters of specialized cell-surface receptors called integrins, which stimulate
differentiation of fibroblast into myofibroblasts (Eckes et al., 2000; Gabbiani, 2003).
Focal adhesion kinase (FAK) mediated mechanotransduction was shown to be required
for TGFβ- induced myofibroblast differentiation. This was demonstrated using FAKdeficient fibroblasts, or using the FAK/src inhibitor PP2 (Liu et al., 2007). We found that
FAK contributes to the persistent fibrotic phenotype of SSc fibroblasts (Shi-wen et al.,
2012). Indeed, cell attachment to the ECM and consequent activation of FAK is required
for myofibroblast differentiation in response to TGFβ1 (Thannickal et al., 2003; Liu et
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al., 2007; Ding et al., 2017). Mechanical tension from the ECM is communicated through
integrins to the nucleus through SMA-containing stress fibers. Integrins are heterodimers
composed of one α- and one β- subunit. The main integrins that are involved in adhesion
to type I collagen include: α1β1, α2β1, and α11β1 (Schiro et al., 1991; Pozzi et al., 1998;
Carracedo et al., 2010). The integrin subunit β1 is as a key, central mediator of profibrotic mechanotransduction (Asano et al., 2006; Zhou et al., 2010). Moreover, integrin
αvβ1 mediates activation of latent TGFβ in response to strain and ECM contraction
(Leask et al., 2014; Reed et al., 2015). Partial inhibition of integrin α1β6 prevented
murine pulmonary fibrosis without exacerbating inflammation (Horan et al., 2008). Thus
integrin-mediated adhesion may act, depending on the context, in both parallel and
upstream fashions to promote myofibroblast activity. Mice with fibroblasts that are
deficient in the integrin β1 subunit are resistant to bleomycin-induced skin fibrosis;
however, they also show impaired cutaneous tissue repair and progressive skin thinning,
indicating an essential role for this subunit in dermal homeostasis (Liu et al., 2009, 2010
a).

1.5

CCN matricellular proteins

The cellular communication network (CCN) family of matricellular proteins
nomenclature was officially designated by the HUGO Gene Nomenclature Committee in
October 2018 (Perbal et al., 2018). The family contains six matricellular proteins (CCN1
through 6), each consisting of four conserved cysteine rich domains; an insulin-like
growth factor-binding domain, a Von Willebrand factor type C domain, a
thrombospondin type 1 domain and a CT-terminal domain containing a cysteine knot
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motif (except for CCN5 which lacks a CT domain) (Figure 1.2). These matricellular
proteins are secreted into the ECM where they have a wide variety of regulatory roles.
These roles are just recently being elucidated, and are proposed to interact in a dynamic
spatio-temporal relationship between multiple members of the CCN family and each of
their four domains (Perbal, 2018). The tetra modular structure of the CCN proteins
potentially allows for a wide variety of interactions and functions. Either these functions
overlap or are activated by individual CCN proteins based on the cytokines expressed in
the specific tissue (Perbal, 2018).

1.5.1

CCN2

Formerly known as connective tissue growth factor (CTGF), cellular communication
network factor 2 (CCN2) was first identified as a protein secreted from human umbilical
vein endothelial cells (Bradham et al., 1991). Although not usually expressed under
normal conditions by mesenchymal cells, CCN2 is rapidly induced in fibroblasts in
response to tissue injury (Igarashi et al., 1993; Kapoor et al., 2008). In an in vivo rabbit
model of hypertrophic scarring, antisense-mediated degradation of CCN2 mRNA reduced
excess scarring without significantly affecting wound healing (Sisco et al., 2008). In
healthy tissues, CCN2 is essentially absent, however in bleomycin-induced skin fibrosis
and SSc skin lesions, CCN2 is overexpressed. This suggests CCN2 may be a key
indicator and mediator of fibrotic injury (Igarashi et al., 1996; Liu et al., 2010 b).
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Figure 1.2 Signaling by CCN family members.
CCN1, CCN2 and CCN3 bind TGFβ, fibronectin, integrins, LRP1 and HSPGs as
indicated. CCN proteins appear to signal principally through the C-terminal quarter
(domain IV) to activate adhesive signaling pathways and hence amplify responses to
TGFβ or fibronectin. (Reproduced with permission from: All in the CCN family: essential
matricellular signaling modulators emerge from the bunker (Leask et al., 2006). doi:
10.1242/jcs.03270)
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1.5.2

CCN2 signaling pathway

In response to TGFβ, fibroblasts not only differentiate into myofibroblasts but also
begin to express CCN2 (Igarashi et al., 1993). TGFβ-induced CCN2 expression occurs
via the canonical Smad3 pathway; however, the maintenance of the SSc phenotype is
independent of Smad signaling, as the Smad-binding element in the CCN2 promoter is
required for TGFβ-induced CCN2 promoter activation, but not for the heightened CCN2
promoter activity observed in fibroblasts isolated from fibrotic lesions of SSc patients
(Holmes et al., 2001). CCN2 is expressed in cultured activated myofibroblasts. In a threedimensional co-culture system, SSc epidermal cells also increase CCN2 expression
through interleukin 1 alpha (IL-1α) production and endothelin-1 induced TGFβ
expression (Aden et al., 2010). CCN2 exists in the ECM where it binds to fibronectin and
the fibronectin receptor integrins α4, α5, β1, as well as syndecan-4. Fibroblast attachment
to CCN2 also requires MEK/ERK activity (Holmes et al., 2001). CCN2-deficient
myofibroblasts showed reduced activation via FAK/Akt signaling pathways (Shi-wen et
al., 2006), suggesting that CCN2 may be a fibrogenic marker or mediator.

1.5.3

CCN2 and progressive fibrosis

Use of immunohistochemical and specific ELISA assays has shown that CCN2
protein expression levels correlate with the progression of SSc and pulmonary fibrosis;
possibly indicating that CCN2 is a key regulator in the un-resolving progressive nature of
fibrotic disease (Sato et al., 2000). More specifically, levels of the amino-terminal half of
CCN2 in plasma and dermal interstitial fluid of SSc patients correlate with the severity of
the disease (Dziadzio et al., 2005). Even more importantly, in a transient fibrotic mouse
9

model induced by TGFβ, addition of CCN2 caused the fibrotic lesion to persist. More
specifically, although subcutaneous injection of TGFβ resulted in the formation of
granulation tissue, this fibrotic response was transient, and disappeared after cessation of
application of ligand, despite 7 days of consecutive injections. However injection of
TGFβ1 combined with CCN2 produced a sustained fibrotic response that persisted for at
least 14 days and after cessation of ligand injection (Mori et al., 1999). Thus, CCN2
presents itself as a possible target for therapeutic intervention to interfere with the
progressiveness of SSc, without harming normal fibrogenesis.
Recently, we generated a conditional knockout model that allowed for the direct
testing of whether expression of CCN2 is required for fibrosis. We used a transient
bleomycin model and a progressive fibrosis model involving a fibroblast-specific deletion
of the adhesive signaling suppressor Pten; the fibrotic phenotype seen in both models of
skin fibrosis were rescued by a fibroblast-specific deletion of Ccn2 (Liu et al., 2011, 2013
a). Moreover, targeting CCN2 using a monoclonal antibody partially blocked
TGFβ/CCN2-induced skin fibrosis in mice (Ikawa et al., 2008). Similarly, CCN2
expression is essential for fibrotic models in other organs (Morales et al., 2013; Dorn et
al., 2018; Petrosino et al., 2019). FG-3019, a humanized monoclonal anti-CCN2
targeting antibody which has been under development for ~15 years, has been tested on
mice and showed to block angiotensin II-induced skin fibrosis. (Makino et al., 2017). The
anti-fibrotic effects of FG-3019 was also beneficial in three other murine fibrotic models;
a multiorgan fibrosis model through intraperitoneal injections of CCN2 and TGFβ2, the
unilateral uretal obstruction renal fibrosis model, and an intratracheal bleomycin-induced
pulmonary fibrosis (Wang et al., 2011). When tested in phase 2 human clinical trials on
10

idiopathic pulmonary fibrosis (IPF), results on a small number of patients suggested that
FG-3019 could slow disease progression (Raghu et al., 2016). Investigation into the
control of CCN2 expression may yield an alternative strategy to blocking CCN2
expression. A small molecule inhibitor may be able to penetrate tissue better than a large
antibody and therefore may prove to be an effective therapy.

1.6

YAP/TAZ/TEAD

Yes-associated protein 1 (YAP) and TAZ are mechanosensitive transcriptional coactivators known for regulating the Hippo signalling pathway to control organ size and
tumorigenesis (Huang et al., 2005). YAP/TAZ bind to the TEA domain (TEAD) family
of transcription factors to co-activate gene transcription (Vassilev et al., 2001). Recently,
YAP has been shown to be a downstream regulator of fibroblast activation and
mechanotransduction in physiological and pathological fibrosis (Liu et al., 2015; Piersma
et al., 2015; Mohri et al., 2017; Rinschen et al., 2017). Furthermore, YAP regulation of
mechanotransduction was shown to involve integrins (Elbediwy et al., 2016).
Visudyne© (VP for injection) is an approved drug currently used in the treatment of
macular degeneration. The drug is injected intravenously and photoactivated in the eye.
Interestingly, the non-photoinduced molecular form of VP has been shown to inhibit
YAP activation, with no significant cytotoxicity in human trabecular meshwork cells
below 2 µM (Chen et al., 2015). Thus, YAP presents itself as a possible target for
therapeutic intervention.CCN2 expression is stimulated by an active YAP/TAZ/TEAD
transcription factor complex (Quan et al., 2014). Indeed, we were the first group to
demonstrate the involvement of YAP/TEAD in promoting CCN gene expression (Leask
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et al., 2003). Chromatin immunoprecipitation experiments confirmed that TEAD and
YAP bound the CCN2 promoter (Zhao et al., 2008). Indeed, CCN2 expression can be
used as a readout of activation of the YAP/Hippo pathway (Yang et al., 2018). In human
keratinocytes, knockdown of YAP significantly reduced expression of both CCN1 and
CCN2 (Quan et al., 2014). Thus, a potential non-canonical mechanotransduction
signalling loop emerges, where YAP-mediated CCN2 expression induces stiffening of the
ECM, which further stimulates expression of CCN2 (Figure 1.3). Overexpression of
YAP-mediated CCN2 through the pro-adhesive signaling loop can have severe effects not
only in fibrotic disease, but other diseases as well, as seen in many types of cancer.

1.7

Fibrosis and cancer metastasis

As early as 1998, the CCN family of proteins was linked to cancer and its
progression, as recombinant CCN1 protein was found to promote angiogenesis and tumor
growth (Babic et al., 1998). Later, both CCN1 and CCN2 were discovered to be
expressed in primary tumors and the stromal fibroblasts within the fibrotic tumor stroma
(Rachfal et al., 2004). In fact, CCN1 and CCN2 are overexpressed in many types of
cancer, and have been linked to tumor progression and metastasis (Xie et al., 2004;
Pickles et al., 2007). Indeed, formation of a fibrotic tumor microenvironment is induced
by CCN2, reflecting stiffening of the ECM in fibrosis. Integrin-mediated ECM stiffening,
collagen crosslinking, and formation of FAs were found to enhance breast tumorigenesis
(Levental et al., 2009). Interestingly, there is also evidence that CCN2 and YAP/TAZ are
drivers of cancer metastasis (Shimo et al., 2006; Deng et al., 2007; Warren et al., 2018).
We found that CCN2 expression by tumor stroma is required for melanoma metastasis
(Hutchenreuther et al., 2015). An in vitro YAP or TAZ knockdown strongly reduced the
12

ECM stiffness
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Src
PI3K

FAK

Akt

TAK
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JNK/P38

YAP Nucleus
Pro-fibrotic gene expression

CCN2

Proliferation, survival

Figure 1.3 Proposed fibrotic signaling feedback loop.
Membrane bound integrin heterodimers composed of α5/11β1 subunits bind mechanically
active ECM components such as CCN2, which activates Src/FAK signaling and PI3K.
This activates YAP downstream and translocates it to the nucleus, stimulating expression
of pro-fibrotic genes. ECM components are then secreted from the cell, causing further
stiffening of the ECM and further activation of integrin receptors.
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expression of CCN2, and the ability of these transfected melanoma cells to form lung
metastases in mice following tail injection (Nallet-Staub et al., 2014).
In addition to the involvement of a fibrotic microenvironment in tumorigenesis and
tumor metastasis, there is also evidence that it favors chemotherapy resistance. Activation
of integrin β4 on mammary malignant epithelial cells is required for resistance to
apoptosis (Weaver et al., 2002). Melanoma caused by the BRAF (V600E) mutation,
initially susceptible to targeted therapy, commonly develops chemotherapy resistance
within 6-8 months by a variety of mechanisms, including stimulation of ECM production
and remodeling via integrin-β1/Src/FAK signaling (Frame et al., 2015; Hirata et al., 2015;
Taylor et al., 2018). Indeed, cancer associated fibroblasts (CAFs) are thought to provide
a safe-haven for melanoma through formation of a stiff ECM. It may be possible that
migration of cancer cells through the ECM is aided by the stiffness of a fibrotic tumor
stroma. Primary tumors possibly prime their microenvironment for increased cell motility
through YAP/TAZ mediated expression of CCN2 to increase matrix stiffness and through
formation of focal adhesions. Through this it may be possible for cancer cells to invade
past the basement membrane and move into the blood stream, where they can spread to
other organs (Figure 1.4).
Further support for the notion that activated mechanotransduction promotes tumor
growth and metastasis comes from recent studies showing that YAP/TAZ/TEAD promote
metastasis for numerous types of cancer, including melanoma, lung cancer, breast cancer,
cholangiocarcinoma, gastric cancer, ovarian cancer, colorectal cancer, and oral squamous
cell carcinoma. (Warren et al., 2018). In other regards, invasiveness of melanoma cells
with an activating BRAF mutation was linked to a loss of adhesive signaling suppressor
14

Figure 1.4 YAP/TAZ activation promotes several steps of the metastatic cascade.
Depicted are the critical steps in the metastatic cascade. To spread tumor cancer cells
(brown) undergo an EMT and then must invade through basement membranes and the
surrounding tissue until they encounter a blood or lymphatic vessel. To intravasate they
must then invade between endothelial cells (yellow). While in circulation, tumor cells
interact with immune cells (blue) and platelets (orange). To seed distant organs, cells
must arrest either by becoming lodged in small capillaries, or through active adhesion to
the vessel wall, and then successfully exit the vessel (extravasation). To form a metastatic
tumor, the cancer cell must survive and proliferate in a new microenvironment. Whether
increased YAP/TAZ activity or decreased Hippo pathway activity promotes each of these
steps is indicated. The direction of blood flow is indicated by red dotted arrows. (Used
with open access from Warren et al., 2018 doi: 10.3390/cancers10040115. Copyright © 2018
by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article

15

distributed under the terms and conditions of the Creative Commons Attribution (CC BY)
license (http://creativecommons.org/licenses/by/4.0/).)

phosphatase and tensin homologue, deleted on chromosome ten (PTEN) (Dankort et al.,
2009).

1.8

Phosphatase and tensin homologue

PTEN was first identified as a tumor suppressor frequently lost in a variety of cancers
including brain, breast, and prostate (Li et al., 1997; Steck et al., 1997) PTEN is a dual
specificity protein and lipid phosphatase whose primary target is the second messenger
phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which it hydrolyzes to
phosphatidylinositol (4,5)-bisphosphate (PIP2) (Maehama et al., 1998). PTEN also
blocks phosphatidylinositol 3 kinase (PI3K) by preventing recruitment of AKT
(Stambolic et al., 1998), which directly interferes with the aforementioned
mechanotransduction pathway. In glioma cells, PTEN activity is required for cellular
migration, and there is evidence that this migration is regulated through suppression of
Src (Raftopoulou et al., 2004; Dey et al., 2008). Furthermore, PTEN has also been
reported to dephosphorylate FAK, leading to reduced cell migration and focal adhesion
formation (Tamura et al., 1998)
PTEN protein expression was notably reduced in diffuse cutaneous SSc fibroblasts,
consequently phosphorylation of Akt was also elevated (Parapuram et al., 2011). An in
vivo deletion of Pten, specific to fibroblasts, resulted in spontaneous development of
progressive dermal fibrosis. Loss of Pten resulted in a 3-fold increase in dermal thickness
16

due to excess deposition of collagen (Parapuram et al., 2011). Furthermore, fibrosis
caused by loss of Pten in mouse fibroblasts was dependent on Ccn2 expression (Liu et
al., 2013 a; Parapuram et al., 2014). In these experiments, knockout of Pten or Ccn2 was
induced specifically in fibroblasts through expression of Cre-ER(T) under a fibroblastspecific mouse proα2(I)collagen promoter, along with a 6-kb transcriptional enhancer
located far upstream from the promoter (Zheng et al., 2002; Ramirez et al., 2006). To
investigate the ability of a fibrotic microenvironment to exacerbate melanoma tumor
metastasis, we could use the aforementioned Pten-deficient mouse model to induce a
spontaneous, pathological fibrotic tumor microenvironment, and assess its effect on
tumor metastasis.

1.9

Rationale, objective and hypothesis

Activated mechanotransduction is common in both progressive fibrosis and cancer
metastasis. It is possible the activated tumor stroma reflects the fibrotic
microenvironment seen in SSc, and that a stiffened ECM may aid in primary tumor
metastasis through enhanced pro-adhesive signaling. Verteporfin (VP) has been shown to
suppress the formation of the YAP-TEAD complex (Feng et al., 2016). This allows us to
investigate the role of YAP in pro-fibrotic gene regulation and mechanotransduction,
both in the presence and absence of TGFβ1. I hypothesize that YAP inhibition with VP in
fibroblasts will decrease expression of pro-fibrotic gene clusters both in the presence and
absence of TGFβ1, and that an increased fibrotic microenvironment will enhance the
metastasis of melanoma in vivo. Thus, the objectives for this experiment are as follows:
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1. Assess the alterations to the transcriptome of a fibroblast due to YAP
inhibition during TGFβ-induced fibroblast activation.
2. Assess the effect of an exacerbated fibrotic microenvironment on melanoma
metastasis using a Pten-deficient in vivo fibrotic model.
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2

Materials and Methods
2.1

Cell culture

Human foreskin fibroblasts (HFFs) were purchased from the ATCC and stored in
liquid nitrogen. HFFs were thawed and grown in T75 flasks (Fisher Scientific
Cat#07000229). HFFs were cultured at 37.5 °C and 5% CO2 in high glucose Dulbecco's
Modified Eagle's Medium (DMEM) (ThermoFisher Cat#11995-073), 10% fetal bovine
serum (FBS) (Life Technologies Cat#12483-020) and 1% antibiotic/antimycotic solution
(ThermoFisher Cat#15240-062). Culture medium was replaced every 2-3 days, and cells
were passaged when reaching 80% confluency. They were rinsed with Dulbecco’s
phosphate-buffered saline (DPBS) (ThermoFisher Cat#14040182), detached using
trypsin-EDTA 0.25% (ThermoFisher Cat#25200072) for two minutes, and sub cultured
onto new flasks with fresh medium. After the tenth passage (P10), HFFs were sub
cultured again onto 6-well plates and once they reached 80% confluency, they were
serum-starved by replacing the medium with low glucose DMEM (ThermoFisher
Cat#11885092) with 0.5% FBS and 1% antibiotic/antimycotic.
HFFs (P10) were then treated with Verteporfin (VP) (Sigma-Aldrich CAS#12949778-5). VP was diluted in dimethylsulfoxide (DMSO) (ThermoFisher Cat#TS-20688) to
0.5 µg/ml, and cells were treated with either DMSO as a vehicle control or VP (volumes
of each treatment were equal). Cells were also treated with either VP or DMSO in
parallel with recombinant human TGFβ1 (R&D Systems Cat#240-B-002) at 1 µg/ml.
Total treatment time was 6 hours, with TGFβ1 being added 30 minutes after VP. After
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treatment, the cells were washed with 1 ml DPBS and Trizol was added to begin RNA
extraction.

2.2

RNA isolation

Trizol (Invitrogen cat#15596018) was added, 1 ml per well, plates were scrapped into
tubes and incubated at room temperature for 5 min. Chloroform (Sigma cat#C2432) was
added, 0.2 ml for every 1 ml of Trizol. Samples were shaken vigorously for 15 seconds
and incubated at room temperature for 2-3 min, then were centrifuged at 12,000 RCF for
15 min at 4°C. The upper aqueous layer was transferred to a separate tube (~450 µl per 1
ml Trizol), and 0.5 ml of isopropyl alcohol (Sigma cat#I9516) was added to each tube.
Tubes were inverted 2-4 times and incubated at room temperature for 10 min, followed
by centrifugation at 12,000 RCF for 15 min at 4°C. Supernatant was discarded and the
RNA pellet was washed by adding 1 ml ethanol (100%). Tubes were inverted 2 times and
centrifuged again 12,000 RCF for 7 min at 4°C. The ethanol was removed, and the
washing step was repeated one more time. Following centrifugation, the pellet was dried
by removing the ethanol and allowed to air dry. The RNA pellet was dissolved in 30 µl
UltraPure™ DNase/RNase-Free Distilled Water (cat#10977-023), and frozen at -22°C.

2.3

qPCR analysis

RNA concentrations were determined using a NanoDrop 2000/2000c
Spectrophotometer. To synthesize cDNA, 1 µg of RNA was loaded into 16 µl
UltraPure™ DNase/RNase-Free Distilled Water, in addition to 4 µl Quanta cDNA 5X
qScript supermix (VWR cat#CA101414-112). The mixture was inserted into a
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thermocycler to undergo a polymerase chain reaction (5 min @25°C, 30min @ 42°C,
5min @ 85°C, held at 4°C) to synthesize cDNA.
Quanta SYBR master mix (VWR cat#CA101414-284) were made for various genes
of interest (0.7 µl UltraPure™ DNase/RNase-Free Distilled Water, 5 µl SYBR mix, 0.3
µl primer, for every 4µl cDNA diluted 1:30, plated on a 384-well plate). Primers were
selected using Primer-BLAST and purchased from Life Technologies for the following
targets:
Gene target

Forward primer sequence

Reverse primer sequence

Β-actin

CCTCGCCTTTGCCGATCC

CGCGGCGATATCATCATCG

CTGF/CCN2

GAGGAGTGGCTGTGTGACG

TCTTCCAGTCGGTAACCGC

CCN1

CGGCTCCCTGTTTTTGGAAT

TTGAGCACTGGGACCATGAA

COL1A1

CCCCGAGGCTCTGAAGGTC

GGAGCACCATTGGCACCTTT

COL1A2

CCCCCGGTCCTGCTGGAAGT

GCCAGGGGGACCAACTGCAC

TGFβ1

GCCGTGGAGGGGAAATTGAG

TGAACCCGTTGATGTCCACTT

FN1

CTGGCCAGTCCTACAACCAG

CGGGAATCTTCTCTGTCAGCC

aSMA

CCGGGACTAAGACGGAATC

TTGTCACACACCAAGGCATT

ITGA5

TGCCGAGTTCACCAAGACTG

TGCAATCTGCTCCTGAGTGG

ITGA11

CTGTGGCCAGGGTTCACG

TGTAGCCAAAGAAGGCGGTC

LRP1

GAGTCTGCTTCGTGTGCCTA

CAGTCATTGTCATTGTCGCATCT

EDN1

AGAAACAGTCTTAGGCGCTGA

TGGACTGGGAGTGGGTTTCT

POSTN

TGCCCAGCAGTTTTGCCCAT

CGTTGCTCTCCAAACCTCTA

TNC

GCCAATCATTTGAACAAAGCGG

CCCCTCCCACTTGACCACTA

PTEN

TGTAAAGCTGGAAAGGGACGA

GGAATAGTTACTCCCTTTTTGTCTC

YAP

GAACTCGGCTTCAGGTCCTC

AGGGTCAAGCCTTGGGTCTA
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PCR amplification was conducted with the following heat cycles in a real-time
thermocycler using ABI7900 software (95°C for 2:00min, [95°C for 0:10min, 60°C for
0:30min]x40). β-actin was used for reference, CT values from this housekeeping gene
were used to calculate ∆Ct. Delta-delta CT analysis (∆∆Ct = ∆Ct (treatment) – ∆Ct
(Control average)) yielded fold-change (Fold gene expression = 2^-(∆∆Ct)) for the
treatment groups. The data sets were tested using an unpaired t-test/ordinary one-way
ANOVA (P<0.05) (GraphPad Prism™ 8).

2.4

Microarray analysis

Two separate 6-hour treatments of VP (0.5 µg/ml) on HFFs ± TGFβ1 (1µg/ml) were
performed as described in section 2.1 (n=2). All sample labeling and GeneChip
processing was performed at the London Regional Genomics Centre (Robarts Research
Institute, London, Ontario, Canada; http://www.lrgc.ca). RNA quality was assessed using
the Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA) and the RNA
6000 Nano kit (RIN≥7) (Caliper Life Sciences, Mountain View, CA). Single stranded
complementary DNA (sscDNA) was synthesized from 100 ng of total RNA, as per the
Affymetrix GeneChip WT PLUS Reagent Kit
(http://media.affymetrix.com/support/downloads/manuals/wtplus_reagentkit_assay_manu
al.pdf, Affymetrix, Santa Clara, CA). Total RNA was first converted to cDNA, followed
by in vitro transcription to make cRNA. This cRNA was used to synthesize single
stranded cDNA, and the cRNA was hydrolyzed. 5.5 ug of single stranded cDNA was
synthesized, end labeled and hybridized, for 16 hours at 45°C to a Human Gene 2.0 ST
array. All liquid handling steps were performed by a GeneChip Fluidics Station 450 and
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GeneChips were scanned with the GeneChip Scanner 3000 7G (Affymetrix, Santa Clara,
CA) using Command Console v3.2.4.
Probe level (.CEL file) data were generated using Affymetrix Command Console
v3.2.4. Probes were summarized to gene level data in Partek Genomics Suite v6.6
(Partek, St. Louis, MO) using the RMA algorithm (Irizarry et al., 2003). Partek software
was used to determine gene level ANOVA p-values and fold changes. A Fisher’s exact
test was used to create p-values for GO and KEGG Pathway enrichment. Gene level
ANOVA data input into Transcriptome Analysis Console 4.0.1 software (ThermoFisher)
were filtered by fold-change values to compare gene lists between different treatments.

2.5

Genotyping

DNA was extracted from an ear notch boiled in an acidic solution (25mM
NaOH/0.2mM EDTA) and then neutralized (40mM Tris-HCL). Genotype was
determined through polymerase chain reaction followed by gel electrophoresis. Primers
and amplification conditions were as follows: Cre700 forward:
ATCCGAAAAGAAAACGTTGA reverse: ATCCAGGTTACGGATATAGT (94.0/5:00,
[94.0/0:45, 55.0/0:30, 72/1:00]x35 cycles, 72/7:00), yielding amplicons 500kb in size.
Pten forward: ACTCAAGGCAGGGATGAGC reverse 1:
AATCTAGGGCCTCTTGTGCC reverse 2: GCTTGATATCGAATTCCTGCAGC
(94.0/1:00, [94.0/0:30, 55.0/0:30, 72.0/1:40]x35, 72/7:00)(Lesche et al., 2002).
Fragments were resolved on 1% agarose gels and visualized with ethidium bromide.
Further qPCR analysis to compare Pten expression between Ptenfl/fl + corn oil and Ptenfl/fl
+ tamoxifen groups was performed as described in section 2.3 using the following Pten
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primer (F: ACCAGAGACAAAAAGGGAGTCACAA R:
CGGGTCTGTAATCCAGGTGATTTT).

2.6

Generation of fibroblast specific Pten deficient

mice
Mice hemizygous for tamoxifen-dependent Cre recombinase under the control of a
fibroblast-specific promoter-enhancer cassette from the proα2(I) collagen gene (Zheng et
al., 2002) were bred with mice homozygous for floxed Pten alleles to generate mice
heterozygous for floxed Pten and hemizygous Cre. These mice were bred another
generation to generate the desired genotype: hemizygous Cre and homozygous for floxed
Pten. Male mice at 3 weeks of age with the desired genotype were subjected to
intraperitoneal injections of tamoxifen suspended in corn oil (0.1 ml of 10 mg/ml 4hydroxytamoxifen, Sigma) daily for 5 days to induce a gene knockout specific to dermal
fibroblasts (Pten-/-). Control mice were also generated by injecting a cohort of Ptenfl/fl
mice with only corn oil, the vehicle for the tamoxifen. Mice required 60 days following
tamoxifen treatment to develop a fibrotic phenotype.

2.7

Tumor studies

B16F10 murine melanoma cells (ATCC) were cultured in the same high glucose
DMEM medium with 10% FBS, and 1% antibiotic/antimycotic solution as described in
section 2.1, detached using 0.25% trypsin/0.02% EDTA solution, and resuspended in the
same low glucose DMEM, serum-free, and with 1% antibiotic/antimycotic solution as
described in section 2.1 at a density of 3300 cells/µl. Injection of 330,000 cells
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subcutaneously into the right flank of each C57BL/6J mouse (Jackson Laboratory) was
performed 60 days post tamoxifen injection date. Once a palpable tumor was detected,
tumor volume measurements were obtained for all mice for 14 days using a digital caliper
and the following equation: Tumor Volume (mm3) = 1/2(Length of Longest Tumor
Dimension) x (Length of Narrowest Tumor Dimension)2. After 14 days, the mice were
sacrificed, administering heparin before ketamine overdose and cervical dislocation. All
animal protocols were approved by the animal care committee at the University of
Western Ontario. Post-euthanasia, the lungs were flushed with PBS and then inflated by
administering 4% paraformaldehyde (PFA) through the trachea. Lung, tumor with
surrounding skin, and normal skin from the left flank were harvested and fixed in 4%
paraformaldehyde dissolved in PBS (PFA) for 24 hours. Afterwards, tissues were sent to
Robarts Research Institute in 70% ethanol to be processed. Tissues were then embedded
in paraffin, sectioned at 5 µm on a microtome and collected on Superfrost Plus (Fisher
Scientific) slides.

2.8

Skin thickness and lung metastasis analysis

Lung and skin sections were dewaxed in xylene and rehydrated in four descending
concentrations of ethanol (100%, 95%, 80%, 70%), stained with hematoxylin for 1 min
and eosin-y for 7 min. Bright-field images of skin were obtained at 3 varying depths
through the tissue. Skin thickness was then measured using Eclipse software at 6 points
along the skin, from the surface of the epidermis down to the bottom of the dermis, for all
3 depths. Lung sections were imaged, and the area of dense purple metastatic foci was
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assessed as the percentage of the total area of the lung using imageJ software. The two
groups were then compared using an unpaired T-test, and significance was set at P<0.05.

2.9

Tissue homogenization

Skin tissues harvested from the opposite flank of the injected tumor were placed
inside prefilled zirconium bead microtubes (MIDSCI Cat#D1032-30) along with 1 ml of
Trizol. The tissues were then homogenized using a Beadbug Microtube Homogenizer
(MIDSCI Cat#D1030) for 3 individual basic cycles, or until the tissues were completely
homogenized. The Trizol was then transferred to a separate tube where RNA was
extracted as described in section 2.2.

2.10

Immunocytochemistry analysis

A 24-well plate with glass slide inserts was coated with 500µl of collagen type 1
bovine overnight (10µg/ml) (Invitrogen Cat#A1064401). HFFs were then plated (8000
cells/well) and allowed to attach overnight. Cells were then serum starved and treated
with VP or DMSO ± TGFβ as described in section 2.1 for 24 hours, administering
TGFβ1 30 min after VP. Cells were fixed in 4% paraformaldehyde (Sigma), washed in
PBS two times for 2 minutes each, and blocked for 45 minutes in a solution containing
0.1% TritonX-100 in PBS and 10% donkey serum (Jackson Immunoresearch, West
Grove, PA, USA). Cells were then incubated with rhodamine-conjugated phalloidin
(ThermoFisher #R415) diluted 1:1000 in blocking solution for 45 min in the dark. After
washing in PBS two times for 2 minutes, the glass slides were mounted on coverslips
using DAPI fluorescent mounting medium (Vectashield #H-1200). Fluorescence images
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were acquired with a Zeiss Imager M1 fluorescence microscope (Toronto, ON, Canada),
using 360nm to visualize DAPI in blue and 540nm to visualize rho-phalloidin in red.
Images were overlaid using Northern Eclipse software (Empix, Mississauga, ON,
Canada).
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Results

3

3.1
3.1.1

Cell culture-based studies
VP blocks TGFβ1 induced HFF myofibroblast-like phenotype

As an initial proof-of-concept approach to assess if VP could block profibrotic
activity of fibroblasts, I examined changes in fibroblast morphology and
differentiation into myofibroblasts that result in response to treatment with VP and
TGFβ1. HFFs were treated with VP for 24 hours in the presence or absence of
TGFβ1. HFFs that were incubated only with TGFβ1 demonstrated increased
formation of stress fibers consistent with myofibroblast differentiation, as well as
increased cell growth. HFFs treated VP alone demonstrated seemingly fewer
formations of stress fibers, and when combined with TGFβ1, completely inhibited the
ability of TGFβ to induce a myofibroblast-like phenotype in HFFs (Figure 3.1).
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DMSO

TGFβ1

VP

VP + TGFβ1

Figure 3.1 VP blocks TGFβ1 induced HFF myofibroblast-like phenotype
HFFs (passage 10) were plated at approximately 8000 cells/well in a 24-well plate,
precoated with 10µg/ml collagen on glass slides. Cells were treated with either DMSO or
VP and ± TGFβ1 in triplicate for 24 hours. Cells were then fixed with 4% PFA and
blocked in solution and incubated in rho-phalloidin diluted 1:1000 in blocking solution.
Afterwards slides containing the cells were mounted on larger glass slides with DAPI
fluorescent mounting media. Images were taken under fluorescent microscopy. An image
that best represented the average in each condition are provided above. HFFs treated with
TGFβ1 alone displayed increased cellular growth as well as increased differentiation into
myofibroblasts, indicated by formation of SMA stress fibers visualized in red. Treatment
with VP 30 min prior to TGFβ1 completely inhibited this effect (Bar, 100 µm).
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3.1.2

VP significantly inhibits gene expression of CCN2, COL1A1,
COL1A2, and TGFB1, and does not affect expression of
PTEN or YAP
Accumulation of collagen within scar tissue is a characteristic feature of and

leading contributing factor to pathological fibrosis (Hinz et al., 2012; Borthwick et al.,
2013). Over-secretion of collagen in fibrotic lesions by myofibroblasts is not induced by
TGFβ1, at least at the mRNA level (Liu et al., 2014). Therefore, when assessing the
ability of VPs to inhibit collagen expression, we first determined the effect of VP on gene
expression in unstimulated cells (fibroblasts treated with DMSO vehicle control).
Otherwise, VP treatment was administered on HFFs for 6 hours, and a delta-delta CT
qPCR analysis was performed. Data sets were analyzed using a standard unpaired t-test.
Baseline expression of CCN2, COL1A1, COL1A2, and TGFB1 were significantly
inhibited by VP treatment, while expression of PTEN and YAP were not (Figure 3.2).
VP treatment reduced levels of TGFβ1 mRNA, suggesting the intriguing
possibility that the inhibition of a fibrotic phenotype in cells treated with VP could be
caused by an inhibition of TGFβ expression.
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Figure 3.2 VP significantly inhibits gene expression of CCN2, COL1A1, COL1A2,
and TGFB1, and does not affect expression of PTEN or YAP
HFFs were treated with only DMSO or VP for 6 hours and analyzed using qPCR deltadelta CT analysis. All graphs are plots of mean mRNA fold-change ± standard deviation.
Means of the two treatment groups were compared using an unpaired t-test (GraphPad
Prism 8.1). Baseline expression of CCN2, COL1A1, COL1A2, and TGFB1 were inhibited
by VP treatment, while expression of PTEN and YAP were not. (A) CCN2 (P<0.05)
(n=16) (B) COL1A1 (P<0.05) (n=16) (C) COL1A2 (P<0.05) (n=16) (D) TGFB1
(P<0.05) (n=14) (E) PTEN (P=0.990) (n=8) (F) YAP (P=0.686) (n=10)
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3.1.3

VP reduces gene expression of clusters heavily enriched in
ECM secretion and binding in the presence and in the
absence of exogenous TGFβ1
To investigate whether downregulation of pro-fibrotic genes was due to

inhibition of YAP or to decreased expression of TGFβ1, gene level ANOVA fold-change
values from the microarray analysis were filtered to identify downregulated (<-1.5-fold
change) in VP treatments compared with DMSO, as well as VP+TGFβ1 compared with
TGFβ1 (<-1.5-fold change). The two lists of genes were examined using DAVID’s Gene
functional annotation tool to give insight on alterations in gene expression induced by VP
treatment, with and without TGFβ1. Between the two lists of 900+ genes each, 45.4%
were shared. Both lists contained clusters of genes heavily enriched in ECM secretion
and binding (Figure 3.3).

3.1.4

VP reduced 28 potential key regulators of TGFβ1- induced
myofibroblast differentiation
To investigate specific gene targets that were upregulated by TGFβ1 and that

were inhibited by VP, two gene lists were compared. One list contained genes that were
upregulated by TGFβ1 (> 1.5-fold), and the other contained all the genes that were kept
at or below baseline expression by VP in the presence of TGFβ1 compared to DMSO
(<1). On this basis, 28 potential key regulators of myofibroblast differentiation were
found in both lists. Of these 28 targets, the only targets whose mRNA expression was
also reduced by VP treatment in the presence of exogenously added TGFβ1 were ENPP1
and LTBP2 (Figure 3.4).
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Figure 3.3 VP reduces gene expression of clusters heavily enriched in ECM
secretion and binding in the presence and in the absence of exogenous TGFβ1.
Gene expression data obtained by microarray analysis were input into Transcriptome
Analysis Console and two genes lists were generated. One list contained genes that were
downregulated by VP compared to DMSO (< -1.5-fold change). The other list contained
genes that were downregulated by VP in the presence of TGFβ1, compared to TGFβ1
alone (< -1.5-fold change). (A) When the two lists were compared to each other, 45.4%
of the genes were in common. (B) The first list of 908 genes downregulated by VP alone
(< -1.5-fold) were input into DAVID Gene functional annotation tool. Returned clusters
contained genes heavily enriched in transmembrane, cell adhesion, endoplasmic
reticulum, secreted/ECM, ECM/collagen organization, cell-cell adhesion, and cell
migration. (C) The second list of 921 genes downregulated by VP in the presence of
TGFβ1 compared to TGFβ1 alone expression levels (< -1.5-fold) was input into DAVID
Gene functional annotation tool. Returned clusters were enriched in clusters consistent
with the previous list.
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(B) Gene Symbol Fold Change

(A)

ENPP1
LTBP2
BMPR2
EFNB2
CDH2
CDH6
CACHD1
SEMA7A
LRIG1
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SLITRK6
ABCA1
EPHB1
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B4GALT1
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2.32
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PTK7
Heparin binding
2.23
P3H2
Cell migration
1.65
NXPH4
OR52N5
Figure 3.4 VP reduced 28 potential key regulators of TGFβ1- induced
LIPG
myofibroblast differentiation.
LRP4
Microarray results were filtered to create lists of genes altered in each treatment. XYLT1
(A) A list of genes that were up regulated by TGFβ1 (>1.5-fold) was compared CD274
PTGS2
to a list of genes in VP+TGFβ1 that were expressed at baseline or below.

Between these lists, 41 similarities were found, 28 of which were encoding
genes. (B) A list of these similarities with their fold-change values indicating
down regulation with VP+TGFβ1 vs. DMSO. (C) The list of 28 genes was input
into DAVID Gene functional annotation tool. Returned clusters that were most
enriched, similar to clusters in Figure 3.3, involve the ECM and cell migration.
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3.1.5

VP fails to inhibit expression of TGFβ2, TNFAIP6, and CCN2
in the presence of TGFβ1
To give further insight on VP’s inhibition of myofibroblast differentiation, and to

assess VP as a potential candidate for therapeutic intervention in fibrosis, more gene lists
were compared as described previously. One list contained genes that were down
regulated by VP compared to DMSO (<-1.5-fold change), and the other contained a list
of genes that were up regulated in VP+TGFβ1 treatment compared to DMSO. Three
genes were common to both lists: TGFB2, TNFAIP6, and CCN2 (Figure 3.5).

3.1.6

Exogenous TGFβ1 does not interfere with inhibition of profibrotic gene expression induced by inhibition of YAP with VP
To ensure the results from the microarray was not due to deficiency of

endogenous TGFβ1 induced by treatment with VP, additional trials of VP treatment on
HFFs were performed both in the presence and absence of exogenous TGFβ1 (1 µg/ml).
VP treatment ± TGFβ1 was administered on HFFs for 6 hours, and a delta-delta CT
qPCR analysis was performed. Data sets were analyzed using an ordinary one-way
ANOVA. Expression of CCN2, FN1, ITGA5, LRP1, and EDN1 were significantly
inhibited in the presence of VP, irrespective of the presence or absence of exogenous
TGFβ1 (Figure 3.6).
In summary, treatment of fibroblasts with VP blocked formation of a fibrosis-like
phenotype, through reduction in expression of ECM secreting and binding gene clusters,
irrespective of the presence or absence of endogenous or exogenous TGFβ1.
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transforming growth factor beta 2
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2.35

TNFAIP6 tumor necrosis factor, alpha-induced protein 6
CCN2
cellular communication network factor 2

Figure 3.5 VP fails to inhibit expression of TGFβ2, TNFAIP6, and CCN2 in the
presence of TGFβ1
Microarray ANOVA results were input into Transcriptome analysis console 4.0.1 and
filtered to create lists of genes altered in each treatment. (A) A list of 908 genes that
were downregulated by VP (<-1.5-fold) was compared to a list of 739 genes that were
upregulated by VP+TGFβ1 compared to DMSO (>1.5-fold). Between these lists, 6
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similarities were found, of which 3 were encoding
genes. (B) A list of these genes with

their fold change values (VP+TGFβ1 vs DMSO).
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Gene Symbol
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Fold Change (Replicated)
TGFβ1 VP
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-1.22
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-4.16
-1.08
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Figure 3.6 Exogenous TGFβ1 does not interfere with inhibition of pro-fibrotic gene
expression induced by inhibition of YAP with VP
HFFs were treated with either VP or DMSO ± TGFβ1 (1 µg/ml) for 6 hours and RNA
was extracted. A SYBR qPCR was performed and analyzed using the delta-delta CT
method. The mean for each treatment was plotted ± standard deviation. Data sets were
tested for significance using an ordinary one-way ANOVA (GraphPad Prism 8.1).(A)
CCN2 (P<0.05) (n=13) (B) CCN1 (P=0.105) (n=7) (C) FN1 (P<0.05) (n=17) (D) aSMA
(P=0.124) (n=7) (E) ITGA5 test (P<0.05) (n=16) (F) ITGA11 (P=0.578) (n=5) (G) LRP1
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(P<0.05) (n=17) (H) EDN1 (P<0.05) (n=7) (I) POSTN (P<0.05) (n=5) (J) TNC (P=0.062)
(n=17) (K) A chart comparing the fold change values of the replicated qPCR trials to
their microarray ANOVA counterparts for validation of gene expression.
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3.2

in vivo mice studies of fibroblast specific Pten-

deficiency and melanoma tumor metastasis
3.2.1

Pten expression in connective ear tissue was significantly
suppressed in Ptenfl/fl mice administered tamoxifen.
Indeed, inhibition of YAP with VP in vitro successfully prevented a fibrotic

phenotype induced by TGFβ1. To assess the importance of the pro-adhesive signaling
pathway in vivo, we must first ensure that our fibroblast specific Pten- deficient fibrotic
mouse model has the correct genotype and phenotype.
To confirm that Pten was inactivated upon tamoxifen treatment in our mouse
model of fibrosis, we used ear notches as a tissue source from mice in two Ptenfl/fl groups;
one group was treated with corn oil (vehicle control) and the other with tamoxifen. DNA
was extracted from ear tissues, which contained Col1α2-expressing fibroblasts. DNA
from both groups was amplified using the same Pten primer sets. PCR amplification of
DNA from Ptenfl/fl mice administered corn oil returned a single band at just above
1000bp, which is the size for the expected fragment for intact Pten. PCR amplification of
DNA from Ptenfl/fl mice administered tamoxifen returned two bands, one faint band at
just above 1000bp and another much stronger band at 450bp, which is the size of the
expected excised fragment of Pten, indicating a successful inactivation of Pten in Col1α2
expressing fibroblasts (Figure 3.7). Hereafter, the two groups will be termed Ptenfl/fl,
indicating the group of mice treated only with corn oil; and Pten-/-, indicating the group
of mice that received tamoxifen.
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-/- Pten (~450 bp)
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Figure 3.7 Pten expression in connective ear tissue was significantly suppressed in Ptenfl/fl
mice administered tamoxifen.
Suppression of Pten was supported using DNA extracted from ear notches. Post tamoxifen
injections, ear notches were taken, and DNA was extracted. DNA from the ear notches reflects
mostly fibroblasts, but also other cell types (for e.g., epithelial cells). The DNA was primed for
Pten using the same primer for both groups and amplified in a PCR. Amplicons were resolved on
a 1% agarose gel and visualized with ethidium bromide. Ptenfl/fl + corn oil produced amplicons
just above 1000kb, the expected size for floxed Pten. Ptenfl/fl + tamoxifen produced strong bands
at around 450kb, the expected size for the broken fragment of Pten, as well as faint bands at just
above 1000kb, intact Pten (n=3).
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3.2.2

Pten expression in skin of Pten-/- mice is decreased, albeit
non-significant
To further support the suppression of Pten gene transcription, skin tissue from

Ptenfl/fl and Pten-/- was homogenized, and RNA was extracted using the TRIzol method.
Later, cDNA was synthesized and primed for murine Pten primers in a SYBR qPCR.
Delta -delta CT analysis showed a decrease, albeit non-significant, in the amount of Pten
mRNA in the Pten-/- group compared to Ptenfl/fl (Figure 3.8). This result may have
achieved significance if a larger sample size was used.

3.2.3

Skin in Pten-deficient mice was significantly thicker
To support the desired phenotype was acquired by the Pten-/- group in our fibrotic

mouse model, skin sections from both groups were analyzed using H&E staining. Skin
thickness was quantified by measuring the distance from the epidermis to the bottom of
the dermal layer. Measurements were taken for each subject at six points along the image
and repeated for two additional skin sections per subject. Measurements were averaged,
and the two groups were compared using a standard t-test. Dermal thickness was
significantly greater in the Pten-/- group compared to Ptenfl/fl mice, consistent with the
notion that tamoxifen administration induced fibrosis in our model (Figure 3.9).

45

Pten
mRNA Fold-Change

2.0
1.5
1.0
0.5

Pt

Pt

en

en

fl/

fl

- /-

0.0

Figure 3.8 Pten expression in skin of Pten-/- mice is decreased, albeit non-significant.
Skin tissue from both groups was homogenized in microtubes with TRIzol and zirconium
beads. RNA was then extracted using chloroform/TRIzol and amplified into cDNA.
Delta-delta CT analysis using Ptenfl/fl as a control yielded fold-changes that show a trend
towards significant reduction of Pten expressed RNA in Pten-/- group, analyzed using a
standard unpaired t-test (GraphPad Prism 8.1) (P=0.079) (n=3). Plots are mean mRNA
fold-change ± standard deviation. Pten-/- had 4.27-fold less Pten mRNA compared to
Ptenfl/fl.
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Figure 3.9 Pten-/- had significantly increased dermal thickness compared to Ptenfl/fl.
Skin sections from both groups were stained with hematoxylin and eosin-y (H&E) and
visualized under bright-field microscopy. Dermal thickness was measured from the top of
the epidermis to the top of the adipose layer for both groups using ImageJ software. Data
set was tested for a normal distribution using a Shapiro-Wilk test. Thickness mean of
both groups were compared using a standard unpaired t-test and plotted ± standard
deviation. The dermal thickness was significantly greater in the Pten-/- compared to Pten
fl/fl

(P=0.0083) (n=3) Bar, 250 µm.
47

3.2.4

Ptenfl/fl and Pten-/- mice had no significant difference in
melanoma primary tumor growth
To assess the effects of a fibrotic environment on melanoma metastasis, we first

assessed whether there were differences in tumor growth. Increases in the size of the
primary tumor were monitored through a two-week period using digital calipers and an
ellipsoidal equation was used to estimate tumor volumes. Over the entire period of tumor
growth, there was no significant difference in tumor volume between Ptenfl/fl and Pten-/(Figure 3.10).

3.2.5

Melanoma lung tumor metastasis in Pten-/- mice
Based on previous results, it appears that Pten-/- mice exhibit a pro-fibrotic dermal

phenotype, as reported by others (Parapuram et al., 2011, 2014; Liu et al., 2013 b). It was
also predicted that melanoma metastasis might be more prevalent in a fibrotic
microenvironment. To assess this, lung sections from both groups were stained with
hematoxylin and eosin to visualize the presence of dark purple metastatic foci, indicated
by the red arrows (Figure 3.11). Visual inspection suggested the presence of more
metastatic lesions in Pten-/-, but due to the low animal numbers, there was no significant
difference detected between the groups.
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Figure 3.10 Ptenfl/fl and Pten-/- had no significant difference in primary tumor
growth.
Syngeneic B16F10 murine melanoma cells (330,000) were injected subcutaneously in the
right flank of either Ptenfl/fl or Pten-/- C57BL/6 mice 60 days after being administered
corn oil or tamoxifen respectively. On detection of a palpable tumor, volume
measurements using calipers were taken daily for 14 days. Following this the mice were
sacrificed via ketamine overdose and cervical dislocation. Means of tumor sizes were
plotted ± standard deviation and compared at each time point between Ptenfl/fl and Pten-/mice, and no significant difference was found between them at each time point using a
Mann-Whitney test (P=0.264).

49

0.002

0.001

Pt

Pt

en

fl/

fl

- /-

0.000

en

Metastasis area/Lung area (mm3)

0.003

Figure 3.11 Pten-/- mice suggest enhanced melanoma tumor metastasis from primary
tumor to the lungs, however there was no significant difference.
Sections were stained with hematoxylin and eosin-y (H&E) and visualized under brightfield microscopy. The images of the entire lung sections were taken and the percent area
that metastases take up was measured using imageJ software. Means for the two groups
are plotted ± standard deviation and are presented as a fraction of metastasis area/lung
area (mm3), compared using an unpaired standard t-test (P=0.081) (n=3) Bar, 125 µm.
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4

Discussion
4.1

Clinical relevance

Fibrosis is a phenotype seen in many different diseases, with no treatment available
on the market. Almost every organ in the body can undergo physiologic and pathologic
fibrotic reactions. The problem arises when normal tissue repair becomes unregulated and
disrupts tissue homeostasis. This excess deposition of ECM components ultimately leads
to failure of the afflicted organ, involved with 45% of the mortality rates in the Western
hemisphere (Wynn, 2008; Rosenbloom et al., 2010). Furthermore, fibrosis may also
cause mortality through exacerbation of other diseases, such as the metastasis of cancer,
although further investigation in this interaction is required. The key effector cell of
fibrosis, the myofibroblast, is irreversibly differentiated from fibroblasts and
continuously secretes pro-fibrotic proteins and ECM components that stiffen the ECM
and stimulates further differentiation of local cells into myofibroblasts (Gabbiani, 2003;
Leask et al., 2014; Hutchenreuther et al., 2016). This positive feedback loop seen in
pathological fibrosis has no cure and intervention of this process would provide a large
therapeutic benefit to many diseases.
ECM stiffness seen in fibrotic disease can influence gene transcription in a process
known as mechanotransduction. Pro-fibrotic ECM components bind to mechanosensitive
integrin receptors and translate mechanical tension on the cell surface into nuclear
signaling to alter gene expression and drive myofibroblast differentiation (Zhou et al.,
2010). The nuclear effector of this pathway is YAP/TAZ, a heterodimer that activates the
TEAD. Persistent activation and differentiation of myofibroblasts is a key characteristic
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of fibrosis (Gabbiani, 2003; Lagares et al., 2012; Hutchenreuther et al., 2016), which is
perpetuated by heightened integrin-mediated mechanotransduction in a stiff ECM
environment (Asano et al., 2006; Carracedo et al., 2010; Zhou et al., 2010). This
mechanotransduction has been shown to be mediated by YAP (Liu et al., 2015), therefore
interruption of mechanotransduction may provide therapeutic benefit in fibrotic disease.
VP is a drug already approved for macular degeneration. If VP can disrupt
pathological fibrosis through inhibition of YAP, then cross-purposing this drug could be
used to treat a large variety of disease without the need for clinical trials. Drug discovery
for a specific molecular target is a long development process that involves trial and error
and significant investment. Furthermore, completion of clinical trials for a compound can
be an almost decade-long process with even more capital investment. Circumventing this
process by cross-purposing VP for fibrotic treatment could provide a large therapeutic
benefit with very little investment.

4.2

YAP activation occurs in response to

mechanotransduction in otherwise unstimulated
fibroblasts
As expected, TGFβ1 alone induced a myofibroblast-like phenotype, characterized by
increased focal adhesions and actin stress fiber formation. Treatment with VP completely
inhibited this effect (Figure 3.1). Interestingly, SMA fiber recruitment seen in the TGFβ1
treatment was not reflected by changes in mRNA (Figure 3.6). Given SMA’s previously
shown requirement of matrix stiffness (Arora et al., 1994), it is likely that SMA
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expression was not induced due to a lack of a matrix substrate in our cell culture
conditions. The SMA fibers induced by TGFβ1 (Figure 3.1) likely arose as a
consequence of formation of FAs, but without changes in α-SMA mRNA expression.
To give insight into how VP blocks a TGFβ1 induced myofibroblast-like phenotype,
changes in gene transcription induced by VP both in the presence and absence of TGFβ1
were analyzed. Two list of genes downregulated by VP, one with and one without
TGFβ1, were compared to each other, in addition to being input into a DAVID cluster
analysis (Figure 3.3). It seems VP could potentially block TGFβ induced myofibroblast
differentiation through inhibition of genes whose expression positively influences ECM
modulation, and cell binding to other cells and the ECM. However it is unknown which
of these genes were directly influenced by TGFβ1 to elicit this response. VP inhibition of
fibrotic gene clusters in the absence of TGFβ1 compared to baseline tells us in normal
conditions, there is a baseline expression of fibrotic gene clusters, which is inhibited by
VP. If VP blocks activation of YAP mechanotransduction which is required for basal
expression of pro-fibrotic genes, then YAP activation may be required for the ability of
TGFβ1 signalling to induce gene expression.

4.3

Significant reduction of LTBP2 and FN1 prevent

myofibroblast differentiation
To investigate specific gene targets that were induced by TGFβ1 and affected by
YAP inhibition, genes that were upregulated by TGFβ1 were compared to genes VP kept
at baseline or below in the presence of TGFβ (Figure 3.4). DAVID cluster analysis of
these 28 genes returned gene clusters that modulate the ECM, like clusters found
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previously (Figure 3.3). One of the most inhibited genes, latent transforming growth
factor-β binding protein 2 (LTBP2), has recently had its protein product become a clinical
biomarker for IPF progression, which also reflects the level of differentiation of lung
fibroblasts into myofibroblasts (Enomoto et al., 2018). LTBP2 has been shown to interact
with FN1, more specifically LTBP2 failed to integrate into the ECM in the absence of
FN1 (Vehvilainen et al., 2009). FN1 was significantly inhibited by VP both in the
presence and absence of TGFβ1 (Figure 3.6). Thus, it is possible that VP prevents a
TGFβ1 induced HFF myofibroblast-like phenotype through reduction of both LTBP2 and
FN1 mRNA expression, compromising ECM stability and subsequent reduction in
mechanotransduction.

4.4

YAP selectively regulates various key pro-fibrotic

genes
Various pro-fibrotic gene targets were selected to be analyzed through qPCR analysis.
This served to replicate the results from the microarray ANOVA for validation (Figure
3.6). The selection of these important pro-fibrotic gene targets was based on previous
research in the field.
A biomarker of progressive fibrosis in SSc (Sato et al., 2000; Leask et al., 2009;
Morales et al., 2013; Dorn et al., 2018), CCN2 is induced by TGFβ1 signaling and
reduced by treatment with VP. CCN1, another matricellular protein, known for its
involvement in angiogenesis, inflammation, and wound repair, has also been shown to
enhance TGFβ1/SMAD3 signaling and contribute to the fibrogenic response (Kurundkar
et al., 2016). Here, CCN1 is not significantly affected by either TGFβ1 or VP. Both
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CCN1 and CCN2 are thought to be downstream of YAP signaling in basal cell carcinoma
(Quan et al., 2014). Here it seems that although CCN2 is reduced through VP inhibition
of YAP, it is not completely inhibited by it. This is possibly due to the very low level of
basal expression of CCN2 in normal, resting fibroblasts, skewing the relative expression
of VP +TGFβ1 compared to DMSO. In Figure 3.6, CCN2 expression was not
significantly increased by VP +TGFβ1 compared to DMSO.
Fibronectin (FN1) is a fibrillar protein that gives stiffness to the ECM and binds with
integrins to transmit mechanical tension from the ECM through the cell’s cytoskeleton,
αSMA (Cao et al., 2017). FN1 inhibition has also been shown to reduced collagen
expression and improve liver function in liver fibrosis (Altrock et al., 2015). FN1
expression was significantly inhibited by VP both in the presence and absence of TGFβ1,
however SMA was unaffected. Recent findings have shown that α-SMA mRNA
expression is induced by matrix stiffness (Avery et al., 2018).
Integrins, as discussed previously, are the membrane bound receptor that interact with
fibronectin, collagen, CCN2, and other ECM substrates to form focal adhesions and
transmit mechanical tension from the ECM through the cellular cytoskeleton.
Heterodimers of integrins α5β1 bind to fibronectin, collagen and laminin (Chen et al.,
2016 a). Heterodimer α11β1 binds to collagen and α11 transcription has been shown to be
increased by TGFβ1 signaling in fibrosarcoma cell line as well as in primary fibroblasts
(Lu et al., 2010). Here, both integrin subunits α5 and α11 are shown to be unaffected in the
presence of VP and TGFβ1
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Low-density lipoprotein receptor-related protein 1 (LRP1) is a receptor that has been
shown to be involved with signal transmission and endocytosis. More importantly, recent
studies have shown LRP1 to mediate transcytosis of CCN2 in chondrocytes (Kawata et
al., 2012). Furthermore, a smooth muscle cell targeted gene deletion of LRP1 in mice
(smLRP1-/-) resulted in protection of vasculature through mediation of the ECM. More
specifically, smLRP1-/- mice showed increased protein levels of collagen and CCN2 in
the ECM compared to smLRP+/+ (Muratoglu et al., 2013). In myofibroblasts, production
of microvesicles (MV) are stimulated by serum. Inhibition of LRP1 in myofibroblasts
resulted in a significant reduction in MV secretion (Laberge et al., 2018). In HFFs,
inhibition of YAP by VP significantly inhibited expression of LRP1 both in the presence
and absence of TGFβ1. It’s possible that excretion of CCN2 and other pro-fibrotic
proteins into the ECM through MVs could be reduced through VP inhibition of LRP1.
Endothelin-1 (EDN1), one of the three human isoforms typically involved with
vasoconstriction, may also play a role in fibrogenesis. Inhibition of the highly specific
EDN1 receptor A (ETA) decreased collagen deposition and improved lung function in
bleomycin-induced lung fibrosis in mice (Manitsopoulos et al., 2018). As previously
mentioned, TGFβ1 induces endothelial-to-mesenchymal transition (EndoMT), providing
a source of activated myofibroblasts. EDN1 has been shown to potentiate EndoMT while
also inducing expression of TGFβ receptor 1 and 2 genes, suggesting a possible autocrine
mechanism of TGFβ1 induced fibrogenesis (Wermuth et al., 2016). In HFFs, TGFβ1
significantly induced EDN1 expression, which was significantly reduced but not inhibited
by VP in the presence of TGFβ1.
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Periostin (POSTN) is a secreted matricellular protein first found in epithelial ovarian
carcinoma, acting as a ligand on integrins αVβ3 and αVβ5, promoting cell motility (Gillan
et al., 2002). Our previous findings show that CCN2-deficient B16(F10) melanoma cells
demonstrated decreased expression of periostin and decreased the cell’s ability to migrate
through collagen. This was also reflected in vivo, where CCN2-deficient mice
demonstrated a loss of periostin and coincided with decreased metastases of melanoma
from the skin to the lungs (Hutchenreuther et al., 2015). With treatment of VP on HFFs,
expression of periostin is significantly inhibited in both the presence and absence of
TGFβ.
Tenascin-C (TNC) is an ECM glycoprotein which is expressed rapidly in kidney
fibrotic lesions. The mitogenic activity of TNC has also been shown to require the
integrin-FAK signaling pathway (Fu et al., 2017). TNC was also identified as a promoter
of lung adenocarcinoma metastasis (Gocheva et al., 2017). Treatment with VP on HFFs
significantly inhibited TNC expression from TGFβ1 induced expression levels, both in
the presence and absence of TGFβ1.
Most importantly, expression of collagen type 1 alpha 1 and 2 were significantly
inhibited by VP. Excess deposition of collagen into the ECM is a hallmark of fibrotic
disease (Gabbiani, 2003; Wynn, 2008). Administering VP to patients with SSc or other
fibrotic diseases may provide therapeutic benefit through reduction of collagen
expression.
Thus, inhibition of YAP-regulated mechanotransduction with VP has elucidated the
regulation of many important pro-fibrotic targets that all may play a part in influencing
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ECM stiffness. However, it is unclear how much impact each specific target has. It is
most likely that all the affected targets contribute to the fibrotic phenotype in some way,
and that future analysis of ECM modulation should incorporate a multitude of targets.

4.5

Validation of in vivo fibrotic genotype

The genotype of our in vivo mouse model of progressive fibrosis was first assessed by
extracting DNA from ear notches taken post tamoxifen injections. Extracted DNA from
both conditions were primed using the same Pten primer, performed in parallel. Bands
from Ptenfl/fl were intact, while bands from Pten-/- included both intact and fragmented
Pten. The ear notch tissue used to extract DNA contains mainly fibroblasts, but also other
cell types, which may explain the presence of the intact band since our KO model is
targeted towards fibroblasts exclusively. However, this discrepancy may also be due to
the tamoxifen-induced gene KO not being 100% efficient. Later, skin was homogenized,
and this time extracted RNA was primed for Pten. Delta-delta CT analysis of the qPCR
showed a trend towards decrease in Pten mRNA, Pten-/- skin had 4.27-fold less Pten
mRNA than the control group. As before, these results do not reflect only fibroblast
cultures, but other cell types as well. Regardless, the Pten-/- group is verified to have the
intended genotype.

4.6

Loss of fibrotic phenotype

Previously this progressive fibrotic model targeting Pten has increased dermal
thickness 3-fold (Parapuram et al., 2011). However, the mean fold-change of the Pten-/group’s dermal thickness compared to the mean of Ptenfl/fl was only 1.25-fold greater
than the control group. Even more interestingly, our progressive model was given more
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time to progress compared to previous trials, 60 days compared to 45 days. The
phenotype of our Pten-/- skin was not as fibrotic as it should be, even though the mice had
the desired genotype. Our colonies of mice were bred for over 10 generations, therefore
one reasonable explanation for this discrepancy could be genetic drift, the accumulation
of random mutations in the colony. Some of these mutations may affect the desired
phenotype, which would help to explain the large variability in the skin adipose layer and
dermal layer’s thickness, as well as the underwhelming increase in skin thickness in Pten/-

. It is reasonable to expect that the reduced impact on skin thickness would reduce any

expected impact on increasing melanoma metastasis.

4.7

Limitations

Previous analysis of filtered gene lists from the microarray ANOVA were generated
with the criteria that the gene targets were induced by TGFβ1 by at least 1.5-fold. It is
possible that key gene targets regulated by YAP are not induced by TGFβ1 significantly
enough to reach the set threshold and may have been excluded in the analysis. One
example is FN1, which was not induced enough to be included in Figure 3.4 alongside
LTBP2. Furthermore, DAVID gene clusters analysis performed well to divide the list of
genes into functional groups but is not ideal for functional classification of relatively
unknown gene targets. Most notably FN1 and COL1A1 were lacking from notable
fibrotic gene clusters.
Also, it is worth considering the possible inefficiency of VP as an inhibitor of YAP.
The lack of inhibition of various pro-fibrotic gene target expression (Figure 3.5) could be

59

due to incomplete inactivation of YAP. Another recent study concluded that VP did not
seem ideal as an pharmacological inhibitor of YAP-TEAD (Gibault et al., 2016).
Finally, the relatively small sample size for multiple experiments severely limited the
analysis for multiple experiments. All the in vivo experiments had a relatively sample size
(n=3), and results such as Figure 3.8 and 3.11 could have achieved significance if a
larger sample size was used. The sample size for the microarray was also low (n=2).
Changes in the transcriptome may not accurately represent average changes in the
transcriptome for all HFFs. This may describe the small discrepancies in fold-change
values between the microarray and replicated trials in Figure 3.6.

4.8

Future experiments

After comparing the average area melanoma metastasis occupies of the lung, it
was revealed there was no significant difference between the two, however our results
suggest that there might be an increase and a larger number of N values might uncover
this fact. To determine the required group size to achieve a significant difference, a power
analysis was performed using G*Power 3 software. To achieve significance, three more
replicates with similar results per group would be needed (Figure 4.1). This trend
combined with the underwhelming effect of Pten suppression on progressive fibrosis can
supports that further experiments with much larger sample sizes are required to further
elucidate the effect of a fibrotic microenvironment on cancer metastasis.
Furthermore, future experiments could verify YAP as a positive mediator of fibrosis
through a double knockout mouse model of both Pten and Yap. If blocking Yap activity
rescues the fibrotic phenotype induced by Pten knockout, then it further supports a role
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Figure 4.1 Increased mouse group size would be required to be able to accurately
measure significance.
G*Power 3.1.9.2 was used to perform a power analysis on a standard two-tailed T-test
between Ptenfl/fl and Pten-/-. The type of power analysis “A priori” was selected. Effect
size (d=2.32) was calculated and input using the built-in tool using the means and
standard deviation of lung metastasis area for both groups. Values for α and Power were
P=0.05 and P=0.95 respectively, with an allocation ratio N2/N1=1. Output results yielded
required sample size to achieve desired P=0.95 would require three more animal subjects
per group, for a total n=12.
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for YAP as a key regulator of fibrogenesis. Alternatively, VP could be administered in
drug form along with bleomycin or a Pten-/- mouse model to see if Yap inhibition with
VP could prevent induced fibrosis.
Further analysis of YAP activation as a pro-mediator of fibrotic gene transcription
should also be performed. Specifically, analysis of gene expression profiles induced by
inhibition of YAP could be investigated using tools such as IBM’s Watson machine
learning, or artificial intelligence (AI). Advanced mass-data analysis looking for patterns
in data or literature could provide insights into modulation of the ECM in fibrotic disease
that humans can’t perceive (Chen et al., 2016 b).

4.9

Conclusion

Here we confirm our hypothesis that VP inhibition of YAP reduces expression of
fibrogenic gene clusters. Furthermore, VP treatment completely inhibited a TGFβ1induced fibrosis-like phenotype in HFFs. Investigation using microarray analysis
elucidated LTBP2 expression reduced by YAP inhibition both in the presence and
absence of exogenous TGFβ1 and perhaps a key mediator of ECM induced fibroblast
activation. Induced progressive fibrosis in vivo using Pten-deficient mice didn’t induce
the fibrotic phenotype or exacerbate melanoma tumor metastasis as expected, however
due to the lackluster fibrotic phenotype we induced, further trials should be completed. A
more recent study has shown YAP/TAZ activation as a key target for metastatic cancer
(Warren et al., 2018). Perhaps YAP activation in myofibroblast differentiation,
profibrotic gene expression, and cancer metastasis are all linked through increased
mechanotransduction in a fibrotic microenvironment, thus therapeutic strategies to
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prevent over-activation of YAP via verteporfin could be beneficial to a multitude of
diseases.
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